Nonresponding schizophrenia: Differentiation by neurological soft signs and neuropsychological tests

Schizophrenia Bulletin

Volumn 25, Issue 4, 1999, Pages 813-825

  Smith, Robert C ^a   Kadewari, Ramesh P ^b   Rosenberger, John R ^c   Bhattacharyya, Anjan ^d  

^a NEW YORK UNIVERSITY   (United States)

^b Huelten Professional Building ^*  (United States)

^c Treatment Unit   (United States)

^d MANHATTAN PSYCHIATRIC CENTER   (United States)

Author keywords

Frontal lobe functions; Neurological soft signs; Neuropsychological tests; Nonresponding schizophrenia

Indexed keywords

CHLORPROMAZINE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MENTAL DISEASE; NEUROPSYCHOLOGY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; SCHIZOPHRENIA; SCORING SYSTEM; SYMPTOMATOLOGY; TASK PERFORMANCE; TREATMENT FAILURE;

EID: 0033376851     PISSN: 05867614     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.schbul.a033421     Document Type: Article

References (50)

1. Alexander, G.; DeLong, M.; and Strick, P. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annual Review of Neuroscience, 9:357-381, 1986.
2. Alpert, M., and Pouget, E. A scale for the assessment of movement disorders in psychopharmacological studies: The SAMD, in preparation.
3. American Psychiatric Association. DSM-III-R: Diagnostic and Statistical Manual of Mental Disorders. 3rd ed., revised. The Association, 1987.
4. Andersen, S.W.; Masio, H.; Jones, R.; and Tranel, D. Wisconsin card sorting task performance as a measure of frontal lobe damage. Journal of Clinical and Experimental Neuropsychology, 13:909-922, 1991.
5. Andreasen, N.C. The Scale for the Assessment of Negative Symptoms (SANS). Iowa City, IA: The University of Iowa, 1984a.
6. Andreasen, N.C. The Scale for the Assessment of Positive Symptoms (SAPS). Iowa City, IA: The University of Iowa, 1984b.
7. Andreasen, N.; Arndt, S.; Swayze, V.I.; Cizadlo, T.; Flaum, M.; O'Leary, D.; Ehrhardt, J.; and Yuh, W. Thalmic abnormalities in schizophrenia visualized through magnetic resonance image averaging. Science, 266:294-298, 1994.
8. Aylward, E.; Reiss, A.; Barta, P.; Tien, A.; Han, W.; Lee, J.; and Pearlson, G. Magnetic resonance imaging measurement of posterior fossa structures in schizophrenia. American Journal of Psychiatry, 115:1448-1452, 1994.
9. Braun, C.; Hodgins, S.; Toupin, J.; Leveille, S.; and Constantineau, C. Neurological soft signs in schizophrenia: Are they related to negative or positive symptoms, neuropsychological performance, and violence? Archives of Clinical Neuropsychology, 10:489-509, 1995.
10. Buchanan, R., and Heinrichs, D. The Neurological Evaluation Scale (NES): A structured instrument for the assessment of neurological signs in schizophrenia. Psychiatry Research, 27:335-350, 1989.
11. Buchanan, R.; Kirkpatrick, B.; Heinrichs, D.; and Carpenter, W. Clinical correlates of deficit syndrome of schizophrenia. American Journal of Psychiatry, 147:290-293, 1990.
12. Buchanan, R.; Koeppl, P.; and Breier, A. Stability of neurological signs with clozapine treatment. Biological Psychiatry, 36:198-200, 1994.
13. Carpenter, W.; Heinrichs, D.; and Wagman, A. Deficit and nondeficit forms of schizophrenia: The concept. American Journal of Psychiatry, 145:578-583, 1988.
14. Convit, A.; Volavka, J.; Czobor, P.; de Asis, J.; and Evangelista, C. Effect of subtle neurological dysfunction on response to haloperidol treatment in schizophrenia. American Journal of Psychiatry, 151:49-56, 1994.
15. Crow, T. Positive and negative symptoms and the role of dopamine in schizophrenia. British Journal of Psychiatry, 137:383-386, 1980.
16. Dewain, M.; Pandurangi, A.; Lee, S.; Ramachandran, T.; Levy, B.; Boucher, M.; Yozawitrz, A.; and Major, L. Cerebellar morphology in chronic schizophrenic patients: A controlled computed tomography study. Psychiatry Research, 10:97-103, 1983.
17. Flashman, L.; Flaum, M.; Gupta, S.; and Andreasen, N.C. Soft signs and neuropsychological performance in schizophrenia. American Journal of Psychiatry, 153:526-532, 1996.
18. Goldberg, T., and Weinberger, D. Probing prefrontal function in schizophrenia with neuropsychological paradigms. Schizophrenia Bulletin, 14(2):179-183, 1988.
19. Goldstein, G. The neuropsychology of schizophrenia. In: Grant, I., and Adams, K.E., eds. Neuropsychological Assessment of Neuropsychiatric Disorders. New York, NY: Oxford University Press, 1986.
20. Gupta, S.; Andreasen, N.; Arndt, S.; Flaum, M.; Schultz, S.; Hubbard, W.; and Smith, M. Neurological soft signs in neuroleptic-naive and neuroleptic treated schizophrenic patients and in normal comparison subjects. American Journal of Psychiatry, 152:191-196, 1995.
21. Heath, R.; Franklin, D.; Walker, C.; and Keating, J.J. Cerebellar vermal atrophy in psychiatric patients. Biological Psychiatry, 17:569-583, 1982.
22. Heinrichs, D., and Buchanan, R. Significance and meaning of neurological signs in schizophrenia. American Journal of Psychiatry, 145:11-18, 1988.
23. Kane, J.; Hogingfeld, G.; Singer, J.; and Meltzer, H. Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Archives of General Psychiatry, 45:789-796, 1988.
24. Kolakowska, T.; Williams, A.; Jambor, K.; and Ardern, M. Schizophrenia with good and poor outcome III: Neurological soft signs, cognitive impairment and their clinical significance. British Journal of Psychiatry, 146:348-357, 1985.
25. Kolb, B., and Whishaw, I. Performance of schizophrenic patients on tests sensitive to left or right frontal, temporal or parietal function in neurological patients. Journal of Nervous and Mental Diseases, 171:435-443, 1983.
26. Lezak, M. Neuropsychological Assessment. New York, NY: Oxford University Press, 1983.
27. Liddle, P., and Morris, D. Schizophrenic syndromes and frontal lobe performance. British Journal of Psychiatry, 158:340-345, 1991.
28. Martin, P., and Albers, M. Cerebellum and schizophrenia: A selective review. Schizophrenia Bulletin, 21(2):249-250, 1996.
29. Mattis, S. DRS Dementia Rating Scale, Professional Manual. Odessa, FL: Psychological Assessment Resources, Inc., 1973.
30. Meltzer, H. Dimension of clozapine response. British Journal of Psychiatry, 160(Suppl. 17):789-796, 1992.
31. Merriam, A.; Kay, S.; Opler, L.; Kushner, S.; and vanPraag, H. Neurological signs and the positive-negative dimension in schizophrenia. Biological Psychiatry, 28:181-192, 1990.
32. Nelson, H. A modified card sorting test sensitive to frontal lobe defects. Cortex, 12:313-324, 1976.
33. Overall, J.E., and Gorham, D.R. The Brief Psychiatric Rating Scale, Psychological Reports, 10:799-812, 1962.
34. Park, S., and Holzman, P.S. Schizophrenics show spatial working memory deficits. Archives of General Psychiatry, 49:975-982, 1992.
35. Park, S.; Holzman, P.; and Goldman-Rakic, P. Spatial working memory deficits in relatives of schizophrenic patients. Archives of General Psychiatry, 52:821-828, 1995.
36. Perett, E. The frontal lobe of man and the suppression of habitual responses in verbal categorical behavior. Neuropsychologia, 12:323-330, 1974.
37. Perlick, D.; Mattis, S.; Stastiny, P.; and Silverstein, B. Negative symptoms are related to both frontal and non-frontal neuropsychological measures in chronic schizophrenia [Letter]. Archives of General Psychiatry, 49:245, 1992.
38. Saykin, A.; Gur, R.; Gur, R.; Mozley, D.; Mozley, L.; Resnick, S.; Kester, B.; and Stafiniak, P. Neuropsychological function in schizophrenia: Selective impairment in memory and learning. Archives of General Psychiatry, 48:618-624, 1991.
39. Saykin, A.; Schtasel, D.; Gur, R.; Kester, B.; and Mozley, L. Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Archives of General Psychiatry, 51:124-131, 1994.
40. Scheffer, R.; Correnti, E.; Borison, R.; and Mukherjee, S. Temporal stability of neurological signs in first-episode psychotic patients [Abstract]. Biological Psychiatry, 35:715, 1994.
41. Schroder, J.; Niethammer, R.; Geider, F.; Reitz, C.; Binkert, M.; Jauss, M.; and Sauer, H. Neurological soft signs in schizophrenia. Schizophrenia Research, 6:25-30, 1992.
42. Shrout, P.E., and Fleiss, J.L. Interclass correlation: Uses in assessing rater reliability. Psychological Bulletin, 86:420-428, 1979.
43. Simpson, G., and Angus, J. A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica, 212:9-11, 1970.
44. Smith, R.; Chua, J.; Lipetsker, B.; and Bhattacharyya, A. Efficacy of risperidone in reducing positive and negative symptoms in schizophrenia: An open prospective study. Journal of Clinical Psychiatry, 57:460-466, 1996.
45. Smith, R., and Kadewari, R. Neurological soft signs and response to risperidone in chronic schizophrenia. Biological Psychiatry, 40:1056-1059, 1996.
46. Swayze, V.I.; Andreasen, N.; Alliger, R.; Yuh, W.; and Ehrhardt, J. Subcortical and temporal structures in affective disorder and schizophrenia: A magnetic resonance imaging study. Biological Psychiatry, 31:221-240, 1992.
47. Torrey, F. Neurological abnormalities in schizophrenic patients. Biological Psychiatry, 15:381-388, 1980.
48. Volkow, N.; Levy, A.; Brodie, J.; Wolf, A.; Cancro, R.; and Van Gelder, P. Low cerebral metabolism in medicated patients with chronic schizophrenia. American Journal of Psychiatry, 149:686-688, 1992.
49. Wechsler, D. WAIS-R Manual. New York, NY: Psychological Corporation, 1981.
50. Weinberger, D.; Torrey, E.; and Wyatt, R. Cerebellar atrophy in chronic schizophrenia. Lancet, 1:718-719, 1979.